CMA Statement on the Governance of Health Information: A patient-partnered health information governance framework

https://policybase.cma.ca/link/policy14485

POLICY TYPE          Policy document
DATE                2022-06-29
TOPICS              Health information and e-health

Documents
Virtual Care in Canada: progress and potential. Report of the Virtual Care Task Force
https://policybase.cma.ca/link/policy14470

POLICY TYPE Policy endorsement
DATE 2022-02-26
TOPICS Health information and e-health

Documents

VIRTUAL CARE IN CANADA:
PROGRESS AND POTENTIAL

REPORT OF THE VIRTUAL CARE TASK FORCE
JANUARY 2022
Study on Bill S-209, An Act respecting Pandemic Observance Day

https://policybase.cma.ca/link/policy4467

POLICY TYPE | Parliamentary submission
---|---
DATE | 2022-02-09

TOPICS
Health care and patient safety
Ethics and medical professionalism

Documents

Appearance before the Senate
Standing Committee on Social
Affairs, Science and Technology

Study on Bill S-209, An Act
respecting Pandemic
Observance Day

Dr. J. Douglas Pockley
President of the Canadian Medical Association

February 08, 2022

[Image of Canadian Medical Association logo]
CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE  Parliamentary submission
DATE  2021-12-15
TOPICS  Health care and patient safety
  Ethics and medical professionalism

Documents
Vaccine acceptance

https://policybase.cma.ca/link/policy14450

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents

Vaccine acceptance

Policy recommendation

1. High-risk settings for vaccine acceptance need to be established, with support from public health. Subtle methods, such as the use of social media platforms, should be used creatively and collaboratively to encourage uptake and address common barriers.

2. It is important to engage health workers and their organizations. It is advisable to consider local advocacy, networking, and other strategies to address concerns and assist in vaccine acceptance.

3. The task is to implement a plan that prioritizes the needs of high-risk settings while ensuring that the strategies are effectively communicated. The plan should be developed in consultation with relevant stakeholder groups, including health workers and their organizations.

4. It is important to ensure that the plan is inclusive and considers the needs of all populations, including marginalized communities.

5. It is crucial to prioritize the health and safety of health care workers and their families. The plan should include strategies to support their well-being and address any potential barriers to vaccine acceptance.

6. Legal and regulatory frameworks should be reviewed to ensure that they support the implementation of the plan, including the provision of time off to receive the vaccine.

7. The plan should be monitored and evaluated to ensure its effectiveness and to identify areas for improvement.

END OF POLICY DOCUMENT

CMA Policybase - Canadian Medical Association
Return to school during COVID-19
https://policybase.cma.ca/link/policy14452

POLICY TYPE: Policy document
DATE: 2021-08-21
TOPICS: Health care and patient safety, Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)
https://policybase.cma.ca/link/policy14453

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Interchangeability of vaccines (vaccine mixing)

Policy position recommendation

1. The CMA recommends the interchangeability of vaccines as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used. This includes the use of different vaccine brands when a single vaccine is not available.

2. The CMA recommends that healthcare providers and public health officials coordinate vaccine distribution and administration to ensure that all available vaccines are used.

Interchangeability of vaccines

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

Interchangeability of vaccines with similar characteristics

Interchangeability of vaccines with similar characteristics

1. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.

2. The interchangeability of vaccines with similar characteristics is recommended as a means of increasing vaccine coverage and accessibility, and ensuring that all available vaccines are used.
Firearms Control (Update 2021)
https://policybase.cma.ca/link/policy14401

POLICY TYPE
Policy document

DATE
2021-07-15

REPLACES
Firearms control (Update 2001)

TOPICS
Population health, health equity, public health
Health care and patient safety

Documents
Digital Health Care and Competition – a perspective from The Canadian Medical Association
https://policybase.cma.ca/link/policy14444

POLICY TYPE  Parliamentary submission
DATE  2021-06-25
TOPICS  Health information and e-health

Documents
Enhancing equitable access to virtual care in Canada: Principle-based recommendations for equity
https://policybase.cma.ca/link/policy14447

POLICY TYPE
Policy endorsement

DATE
2021-04-30

TOPICS
Population health, health equity, public health
Health information and e-health

Documents
The Canadian Interdisciplinary Palliative Care Competency Framework
https://policybase.cma.ca/link/policy14439

POLICY TYPE  Policy endorsement
DATE        2020-12-05
TOPICS      Health care and patient safety
            Population health, health equity, public health

Documents
Committee Appearance – Justice and Human Rights: Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
https://policybase.cma.ca/link/policy14374

POLICY TYPE: Parliamentary submission
DATE: 2020-11-05
TOPICS: Health care and patient safety

Documents

Committee Appearance – Justice and Human Rights: Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
November 5, 2020
CMA Pre-budget Submission

https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
Physician practice, compensation, forms
Health information and e-health
Health care and patient safety
Health systems, system funding and performance

Documents
CMA Statement on Racism
https://policybase.cma.ca/link/policy14245

POLICY TYPE
Policy document

DATE
2020-06-02

TOPICS
Ethics and medical professionalism
Health care and patient safety

Documents
Responding to the COVID-19 pandemic: Federal measures to recognize the significant contributions of Canada’s front-line health care workers

https://policybase.cma.ca/link/policy14211

POLICY TYPE: Parliamentary submission

DATE: 2020-05-28

TOPICS: Health care and patient safety

Documents

[Image of CMA Brief]

Responding to the COVID-19 pandemic:

Federal measures to recognize the significant contributions of Canada’s front-line health care workers.
Framework for Ethical Decision Making During the Coronavirus Pandemic

https://policybase.cma.ca/link/policy14133

POLICY TYPE
Policy document

DATE
2020-04-01

TOPICS
Ethics and medical professionalism
Health care and patient safety

Documents
Emergency federal measures to care for and protect Canadians during the COVID-19 pandemic

https://policybase.cma.ca/link/policy14132

POLICY TYPE  Parliamentary submission
DATE  2020-03-16
TOPICS  Health care and patient safety

Documents
Appropriateness in health care
https://policybase.cma.ca/link/policy11516

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2014-12-06
TOPICS  Health care and patient safety

Appropriateness in Health Care

Summary:
The policy discusses the concept of appropriateness in health care and its relevance to patient safety. It highlights the importance of ensuring that care is ethical, evidence-based, and meets patients' needs appropriately. The policy emphasizes the role of physicians in promoting appropriate care and preventing unnecessary or harmful interventions.

Policy

1. Physicians should provide care that is appropriate to the patient's needs and circumstances.
2. The decision to initiate treatment should be based on the best available evidence and the patient's preferences.
3. Healthcare providers should engage in ongoing professional development to improve their understanding of appropriate care and patient safety.
4. Collaboration among healthcare providers is essential to ensure appropriate care and patient safety.

Conclusion:
The policy underscores the importance of appropriate care in achieving patient safety and optimal health outcomes. Healthcare providers are encouraged to continually assess and improve their practice to ensure that care is aligned with patient needs and evidence-based guidelines.
Guiding principles for the optimal use of data analytics by physicians at the point of care

https://policybase.cma.ca/link/policy11812

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2016-02-27

TOPICS
Health information and e-health

Documents

Guiding Principles for the Optimal Use of Data Analytics by Physicians at the Point of Care

Executive Summary

Electronic health records (EHRs) are being used more widely and include increasingly more data. A majority of physicians in Canada have implemented electronic health records (EHRs). While physicians are able to access and use EHRs in their practices, they need to be aware of the potential benefits and risks for using and sharing health information, which provides opportunities for the use of data analytics.

By data analytics, we mean using the process of analyzing clinical data to produce evidence and evidence-based clinical practice. In our health system, this includes using health information to support evidence-based practice, to improve the quality of care, and to provide value to health caregivers or from data science and statistics, such as data mining, which is the process of finding patterns in a collection of data. However, the use of data analytics in healthcare requires that approaches may be sensitive to privacy and confidentiality issues.

Optimal use of data analytics in healthcare is having the right balance between managing the availability of data for innovation and maintaining privacy. Healthcare policies for the use of data analytics need to balance the benefits derived from using data while responding to concerns for access to EHR data, including the following:

1. All stakeholder groups need to be involved in setting and maintaining a workable value framework for optimal use of data analytics

CMA Policybase - Canadian Medical Association
Report of the Virtual Care Task Force
https://policybase.cma.ca/link/policy14440

POLICY TYPE Policy endorsement
DATE 2020-02-29
TOPICS Health information and e-health

Documents